-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
ArriVent BioPharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q4 2024.
- ArriVent BioPharma, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$23.7M, a 2.54% decline year-over-year.
- ArriVent BioPharma, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$94.3M, a 26.4% decline year-over-year.
- ArriVent BioPharma, Inc. annual Operating Income (Loss) for 2024 was -$94.3M, a 26.4% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)